Literature DB >> 10445600

A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years.

J J Egan1, C Maden, S Kalra, J E Adams, R Eastell, A A Woodcock.   

Abstract

Cross-sectional studies have suggested that asthmatic patients receiving high dose inhaled corticosteroids and intermittent courses of oral corticosteroids have reduced bone mass. This prospective 2-yr study was undertaken to evaluate changes in bone density of patients receiving high doses of inhaled corticosteroids. Patients (n = 33) (males aged 18-50 yrs, females aged 18-40 yrs) on inhaled corticosteroids 1,000-2,000 microg x day(-1), were randomized in a double-blind fashion to either fluticasone propionate (FP) 1,000 microg x day(-1) or beclomethasone dipropionate (BDP) 2,000 microg x day(-1). In parallel, three open control groups of the same age range were studied: asthmatics (n = 8) receiving low dose inhaled corticosteroids (< or =400 microg x day(-1)) (group A); chronic, severe asthmatics (n = 8) receiving oral corticosteroids (> or =10 mg x day(-1) (group B); and healthy untreated volunteers (n = 7) (group C). Bone densitometry scans (quantitative computed tomography (QCT) of spine; dual X-ray absorptiometry of spine, femoral neck, and single photon absorptiometry of forearm) were performed at baseline and after 6, 12 and 24 months of treatment. Biochemical bone marker measurements (serum osteocalcin, bone alkaline phosphatase, pro-collagen type 1 carboxy terminal propeptide, deoxypyridinoline and C-telopeptide of type 1 collagen) were collected every 3 months. Fifteen FP (mean age 36 yrs, six male) and 9 BDP patients (mean age 33 yrs, five male); completed the study. At 0 months, mean bone mineral density (BMD) was lower in patients receiving inhaled corticosteroids (both low dose and high dose) than in normal volunteers. In the FP-treated group, mean vertebral trabecular BMD quantitative computed tomography remained stable with no evidence of decline, whereas there was some decline in the BDP-treated group. The treatment difference between FP and BDP was statistically significant in favour of FP for quantitative computed tomography measurements after 12 months (p = 0.006) and 24 months (p = 0.004). This study suggests that over 24 months, changes in bone density are minimal in patients on high-dose inhaled corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445600

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  COPD death rates: projecting a female trajectory.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2004-02-03       Impact factor: 8.262

2.  Normative bone mineral density z-scores for Canadians aged 16 to 24 years: the Canadian Multicenter Osteoporosis Study.

Authors:  Wei Zhou; Lisa Langsetmo; Claudie Berger; Jonathan D Adachi; Alexandra Papaioannou; George Ioannidis; Colin Webber; Stephanie A Atkinson; Wojciech P Olszynski; Jacques P Brown; David A Hanley; Robert Josse; Nancy Kreiger; Jerilynn Prior; Stephanie Kaiser; Susan Kirkland; David Goltzman; Kenneth Shawn Davison
Journal:  J Clin Densitom       Date:  2010-05-31       Impact factor: 2.617

Review 3.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

4.  Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study.

Authors:  Gulden Pasaoglu; Haydar Gok; Dilsad Mungan; Birkan Sonel; Peyman Yalcin; Zeynep Misirligil
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

5.  Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years.

Authors:  A E Tattersfield; G I Town; O Johnell; C Picado; M Aubier; P Braillon; R Karlström
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

Review 6.  Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review.

Authors:  Florent Richy; Jean Bousquet; George E Ehrlich; Pierre J Meunier; Elliot Israel; Hirotoshi Morii; Jean-Pierre Devogelaer; Nicola Peel; Muriel Haim; Olivier Bruyere; Jean-Yves Reginster
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

7.  Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.

Authors:  I A Campbell; J G Douglas; R M Francis; R J Prescott; D M Reid
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

8.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

Authors:  P Szulc; P D Delmas
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

Review 9.  Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.

Authors:  Ratika Gupta; Luz S Fonacier
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 10.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.

Authors:  Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc
Journal:  Can Respir J       Date:  2007-09       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.